ABSTRACT
BACKGROUND: Many in-person congresses have shifted to a virtual format owing to coronavirus disease 2019 (COVID-19). We assessed carbon emissions savings associated with virtual attendance at international medical congresses for a mid-sized pharmaceutical company, to identify which aspects are driving the carbon cost. METHODS: We assessed carbon emissions that were the responsibility of company attendees (including their guests) for the most attended congresses by employees (American Society of Clinical Oncology [ASCO], European Neuroendocrine Tumor Society [ENETS], European Society for Medical Oncology [ESMO], World Congress for NeuroRehabilitation [WCNR]). For in-person estimates, we considered travel, accommodation and congress attendance; for online estimates, we considered office and internet-related energy use. Emissions were defined using recognised data sources. RESULTS: For 1723 anticipated in-person attendees, calculated total carbon emissions were 3,262,574 kgCO2e (mean per in-person company attendee, 1894 kgCO2e: ASCO, 4172; ESMO, 1479; WCNR, 1153; ENETS, 1009). For context, the average UK resident's annual carbon footprint is 5600 kgCO2e. Travel accounted for 91-96% of total emissions, mainly through long distance and business-class air travel. Calculated total carbon emissions associated with 1839 virtual attendees were 19,095 kgCO2e (mean per virtual company attendee, 10.4 kgCO2e; equivalent to approximately 0.3-1.1% of in-person attendance emissions across all four congresses assessed). CONCLUSION: Carbon emissions associated with virtual attendance were two orders of magnitude lower than for in-person attendance, and therefore the benefits of in-person attendance at medical congresses must be balanced against the carbon cost. Due diligence around who should attend and how they should travel to face-to-face meetings, and consideration of hybrid and domestic satellite options could be part of a balanced solution to reducing carbon emissions.